| 查看: 209 | 回复: 0 | |||
| 当前主题已经存档。 | |||
abcd888898银虫 (正式写手)
|
[交流]
【转帖】Novo Nordisk starts phase 1 trial with long-acting oral GLP-1 analogue
|
||
|
Emisphere earns 2 million US dollar milestone payment(13 Jan 2010) Novo Nordisk today announced that it has initiated its first phase 1 clinical trial with a long-acting oral GLP-1 analogue (NN9924). This milestone releases a 2 million dollar payment to Emisphere Technologies, Inc., whose proprietary Eligen® Technology is used in the formulation of NN9924. GLP-1 (Glucagon-Like Peptide-1) is a natural hormone involved in controlling blood sugar levels. It stimulates the release of insulin only when blood sugar levels become too high. In people with type 2 diabetes, GLP-1 secretion is often impaired. The aim of the trial, which is conducted in the UK, is to investigate the safety, tolerability and bioavailability of NN9924 in healthy volunteers. Results from the trial, which is planned to enrol about 155 people, are expected to be reported in 2011. There are many challenges in developing a formulation of GLP-1 for oral use, in particular obtaining adequate bioavailability (absorption of the drug in the body). NN9924 addresses some of the key challenges, and utilises the Eligen® formulation technology from Emisphere to facilitate GLP-1 absorption from the gut. |
回复此楼» 猜你喜欢
二乙烯基砜的合成路径
已经有4人回复
-
NSCLC脑转移肿瘤模型
已经有0人回复
-
药物学论文润色/翻译怎么收费?
已经有77人回复
-
求一株[b]敲除MTAP(human)的HCT-116(人结肠癌细胞)/b]细胞
已经有0人回复
-
求助！求美国食品化学药典内容：FCC13【低聚果糖专论】
已经有0人回复
-
CHP-134这个细胞系哪里有？
已经有0人回复
-
【2027博士申请】纳米药物递送方向
已经有5人回复
-
消耗微量API，便可预测早期研发阶段的HME工艺可行性
已经有0人回复
-
反应液中苯酐除去
已经有1人回复
-
27年环评考试资料
已经有1人回复